Project Grant HT94252510401
Award Date
5/15/25
Completion Date
5/14/29
Dollars Obligated
$2.5M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
New York, NY 10022, USA
Similar Awards
This federal Project Grant award for $847,501.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by Weill Medical College of Cornell University on the role of BCL-XL in breast cancer metastasis and therapy. The project aims to advance the understanding of cellular mechanisms underlying breast cancer progression and investigate potential therapeutic interventions. As a leading academic medical...
This $312,610 federal Project Grant was awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports advanced biomedical research at Weill Medical College of Cornell University focused on the "Role of Functional Factors in AR Reprogramming and Progression of Prostate Cancer." The 2-year grant, running from September 2024 to September 2026, will fund cutting-edge investigations into the cellular mechanisms driving...
This federal Project Grant award from the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420) provides $808,141.00 to Weill Medical College of Cornell University to conduct research targeting inflammatory pathways in breast cancer brain metastases. The purpose is to develop treatments for edema and radiation necrosis using anti-VEGF ultrasmall particle therapy. The project will be performed from February 1, 2025 through January 31, 2027. As...
The U.S. Defense Health Agency awarded a $1,522,278 Project Grant to Weill Medical College of Cornell University on September 30, 2024 under the Military Medical Research and Development program (CFDA 12.420). The grant supports a research project titled "Decoding Bone Metastasis in Prostate Cancer: A Multimodal Approach Integrating Genomics and Imaging Data." The project aims to advance scientific understanding and improve treatment of bone metastasis in prostate cancer patients...
This federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $762,750.00 to Weill Medical College of Cornell University to conduct "NUTRITION-BASED PROGRAMMING OF DENDRITIC CELLS FOR OVARIAN CANCER IMMUNOTHERAPY" research. The award period runs from May 1, 2025 to April 30, 2028. This grant supports advanced biomedical research initiatives focused on transforming healthcare for...
This $1,518,817 federal Project Grant award, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research conducted by Weill Medical College of Cornell University to characterize the role of 3'-UTR biology as a mechanism of therapy response in high-risk prostate cancer. The research aims to advance understanding of the cellular processes underlying therapy resistance in aggressive prostate cancer, with the goal of developing...
This federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $988,740.00 to Weill Medical College of Cornell University to conduct research on "GENOMICALLY INFORMED MORPHOLOGICAL STROMAL SIGNATURES TO PREDICT LETHAL PROSTATE CANCER". The award period runs from June 15, 2025 to June 14, 2028. As a renowned academic medical institution, Weill Medical College of Cornell University will...
This $358,264 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports research at Cornell University focused on targeting inflammatory pathways in breast cancer brain metastases. The research aims to develop anti-VEGF ultrasmall particle therapy to treat edema and radiation necrosis. The award period is from February 1, 2025 to January 31, 2027. The research is expected to transform healthcare for military...
This $677,998 federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) supports research by the Weill Medical College of Cornell University to target extrachromosomal DNA (ecDNA) to reverse therapy resistance in urothelial cancer. The 3-year award, running from September 1, 2024 to August 31, 2027, will enable the institution to conduct advanced biomedical research focusing on innovative approaches to...
This federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $1,356,000.00 to the Weill Medical College of Cornell University to conduct research on the "RESTORATION OF CLEAR CELL RENAL CELL CARCINOMA TUMORIGENICITY BY CELL REPROGRAMMING." The 4-year award, with a performance period from November 1, 2024 to October 31, 2028, supports advanced biomedical research initiatives focused on...